Welcome to REGULAXIS, a French Innovative Biotechnology Company based at BIOCITECH, the technology park of life science of Paris North area . The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies.
Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record.
REGULAXIS leads its R&D on its own premises, particularly in regard to the chemical synthesis, biology, in vitro and in animals (rodents), and developes therapeutic molecules by establishing targetted collaborations with academic researchers as well as partnerships with companies interested in developing therapeutic molecules.
Regulaxis is member of Medicen the Paris
cluster for innovative therapies and advanced technologies in healthcare.
REGULAXIS also is dedicated to R&D in Regenerative Medicine . In particular, the company will focus on reconstitution and repair of articular cartilage by stimulation of chondrocytes, cartilage-forming cells, necessary for the treatment of osteoarthritis and cartilage recovery after traumatic lesions.
Regulaxis won a prize of the "15eme concours national d’aide à la création d’entreprises de technologies innovantes" organize by the French Research Ministery in emergeance category.
Regulaxis project finished 15th on 81 companies from 16 european countries at the the Universal Biotech Innovation Prize .
